XOMA Royalty (XOMA) Gains from Investment Securities (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Gains from Investment Securities came in at $2.1 million in Q1 2026, up 430.04% year-on-year from $400000.0 in Q1 2025, and down 21.74% quarter-over-quarter from $2.7 million in Q4 2025.
XOMA Royalty (XOMA) Gains from Investment Securities (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Gains from Investment Securities across 17 years of filings, most recently posting $2.1 million for Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $2.1 million, up 430.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.1 million (up 227.03% YoY), and the FY2025 annual result was $2.2 million, down 11.27% from the prior year.
- Gains from Investment Securities came in at $2.1 million for Q1 2026 at XOMA Royalty, down from $2.7 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $2.7 million in Q4 2025 to a low of -$2.6 million in Q4 2024.
- The 5-year median for Gains from Investment Securities is $180000.0 (2023), against an average of $474367.4.
- Across the five-year window, Gains from Investment Securities soared 1300.33% in 2022 and tumbled 678.67% in 2024, its largest moves.
- XOMA Royalty's Gains from Investment Securities stood at -$1.4 million in 2022, then jumped by 132.1% to $450000.0 in 2023, then sank by 678.67% to -$2.6 million in 2024, then surged by 204.03% to $2.7 million in 2025, then fell by 21.74% to $2.1 million in 2026.
- The last three Gains from Investment Securities figures came in at $2.1 million (Q1 2026), $2.7 million (Q4 2025), and $9936.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | XOMA Royalty | 5.48 Mn | -60.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.12 Mn |
| Mar 31, 2026 | 2.12 Mn |
| Dec 31, 2025 | 2.71 Mn |
| Dec 31, 2025 | 2.71 Mn |
| Sep 30, 2025 | 9,936.00 |
| Sep 30, 2025 | 9,936.00 |
| Jun 30, 2025 | 9,936.00 |
| Jun 30, 2025 | 9,936.00 |
| Mar 31, 2025 | 400,000.00 |
| Mar 31, 2025 | 400,000.00 |
| Dec 31, 2024 | -2.60 Mn |
| Dec 31, 2024 | -2.60 Mn |
| Sep 30, 2024 | 2.48 Mn |
| Sep 30, 2024 | 2.48 Mn |
| Jun 30, 2024 | 34,170.00 |
| Jun 30, 2024 | 34,170.00 |
| Mar 31, 2024 | 275,000.00 |
| Mar 31, 2024 | 275,000.00 |
| Dec 31, 2023 | 450,000.00 |
| Dec 31, 2023 | 450,000.00 |